0 2 FEB 2004

QUERY CONTR	OL FORM	RTIS USE ONLY			
Application No.	09206132	Prepared by	ewi	Tracking Number	05874534
Examiner-GAU	GUZO	Date	1-23-04	Week Date	12-15-03
	1636	No. of queries	-1~	IFW	

JACKET				
a. Serial No.	f. Foreign Priority	k. Print Claim(s)	p. PTO-1449	
b. Applicant(s)	g. Disclaimer	I. Print Fig.	q. PTOL-85b	
c. Continuing Data	h. Microfiche Appendix	m. Searched Column	r. Abstract	
d. PCT	i. Title	n. PTO-270/328	s. Sheets/Figs	
e. Domestic Priority	j. Claims Allowed	o. PTO-892	t. Other	

SPECIFICATION	T MESSAGE
	MESSAGE
a. Page Missing	Page 1 line 6
b. Text Continuity	Is there date missing
c. Holes through Data	after word "grant"?
d. Other Missing Text	V
e. Illegible Text	Please advise
f. Duplicate Text	Thank you
g. Brief Description	
h. Sequence Listing	
i. Appendix	
j. Amendments	
k. Other	
!	
CLAIMS	
a. Claim(s) Missing	
b. Improper Dependency	
c. Duplicate Numbers	
d. Incorrect Numbering	initials
e. Index Disagrees	RESPONSE No. Claringed wording slightly.
f. Punctuation	(cons attached)
g. Amendments	
h. Bracketing	
i. Missing Text	
j. Duplicate Text	
k. Other	
	initials

a

TUMOR CELLS MODIFIED TO EXPRESS B7-2 AND B7-3 WITH INCREASED IMMUNOGENICITY AND USES THEREFOR

def 2/2/04 Government Funding

Work described herein was supported under grant awarded by the National Institutes of Health. The U.S. government therefore may have certain rights to this invention.

100 No.>10

Related Applications

This application is a Continuation-in-part of U.S. Serial No. 08/147,773 filed November 3, 1993 entitled "Tumor Cells Modified to Express B7-2 and B7-3 with Increased Immunogenicity and Uses Therefor". The contents of this application is incorporated herein by reference.

15

20

25

30

35

Background of the Invention

Induction of a T lymphocyte response is a critical initial step in a host's immune response. Activation of T cells results in T cell proliferation, cytokine production by T cells and generation of T cell-mediated effector functions. T cell activation requires an antigen-specific signal, often called a primary activation signal, which results from stimulation of a clonally-distributed T cell receptor (hereafter TcR) present on the surface of the T cell. This antigen-specific signal is usually in the form of an antigenic peptide bound either to a major histocompatibility complex (hereafter MHC) class I protein or an MHC class II protein present on the surface of an antigen presenting cell (hereafter APC). CD4+ T cells recognize peptides associated with class II molecules. Class II molecules are found on a limited number of cell types, primarily B cells, monocytes/macrophages and dendritic cells, and, in most cases, present peptides derived from proteins taken up from the extracellular environment. In contrast, CD8+ T cells recognize peptides associated with class I molecules. Class I molecules are found on almost all cell types and, in most cases, present peptides derived from endogenously synthesized proteins. For a review see Germain, R., *Nature* 322, 687-691 (1986).

It has now been established that, in addition to an antigen-specific primary activation signal, T cells also require a second, non-antigen specific, signal to induce full T cell proliferation and/or cytokine production. This phenomenon has been termed costimulation. Mueller, D.L., et al., Annu. Rev. Immunol. 7, 445-480 (1989). Like the antigen-specific signal, the costimulatory signal is triggered by a molecule on the surface of the antigen presenting cell. A costimulatory molecule, the B lymphocyte antigen B7, has been identified on activated B cells and other APCs. Freeman, G.J., et al., J. Immunol. 139, 3260-3267 (1987); Freeman, G.J., et al., J. Immunol. 143, 2714-2722 (1989). Binding of B7 to a ligand

RPMOSCPAPPLN.DOC